GSK (LON:GSK) Shares Cross Above 200 Day Moving Average – Here’s Why

GSK plc (LON:GSK)’s share price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 1,440 ($18.67) and traded as high as GBX 1,522.50 ($19.74). GSK shares last traded at GBX 1,511 ($19.59), with a volume of 9,054,711 shares.

Analysts Set New Price Targets

A number of research firms recently commented on GSK. Berenberg Bank decreased their price objective on shares of GSK from GBX 1,820 ($23.60) to GBX 1,600 ($20.75) and set a “buy” rating for the company in a research note on Friday, November 29th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 1,805.83 ($23.42).

GSK Stock Up 0.4 %

The business’s 50 day simple moving average is GBX 1,438.13 and its 200-day simple moving average is GBX 1,440. The company has a market cap of £61.31 billion, a price-to-earnings ratio of 24.41, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.

GSK (LON:GSK) last issued its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Sell-side analysts expect that GSK plc will post 175.980975 earnings per share for the current year.

Insider Buying and Selling at GSK

In related news, insider Emma Walmsley sold 120,653 shares of GSK stock in a transaction on Monday, February 10th. The shares were sold at an average price of GBX 1,453 ($18.84), for a total value of £1,753,088.09 ($2,273,195.14). Company insiders own 1.61% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.